---
title: "Weekly Recap | ImmunityBio +0.37%, a quiet rangebound week"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298098580.md"
description: "ImmunityBio (IBRX) closed the week up 0.37% at $8.08, outperforming the S&P 500 by roughly 0.28 percentage points. Trading was rangebound: the stock opened Monday at $7.88, hit a weekly low of $7.73 on Tuesday, then spiked to $8.28 on Wednesday on higher volume before easing back to $8.08 by Friday. There was no major company catalyst this week. The weekly amplitude was 6.98%, while average daily volume came in about a third below the 60-day median, suggesting thinner participation."
datetime: "2026-09-05T07:05:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298098580.md)
  - [en](https://longbridge.com/en/news/298098580.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298098580.md)
generator: "portal-rs"
---

# Weekly Recap | ImmunityBio +0.37%, a quiet rangebound week

## The Week

ImmunityBio (IBRX) closed the week up 0.37% at $8.08, outperforming the S&P 500 by roughly 0.28 percentage points. Trading was rangebound: the stock opened Monday at $7.88, hit a weekly low of $7.73 on Tuesday, then spiked to $8.28 on Wednesday on higher volume before easing back to $8.08 by Friday. There was no major company catalyst this week. The weekly amplitude was 6.98%, while average daily volume came in about a third below the 60-day median, suggesting thinner participation. The latest price sits at $8.08, with a negative price-to-book multiple of -8.18, reflecting its negative book value.

## Analyst Ratings

Four brokers cover the name: three rate it buy and one rates it overweight, with no hold, underweight or sell ratings. The consensus is strong buy, with a consensus target of $12.75, about 57.8% above the latest price of $8.08. Targets range from $12 to $15, showing limited dispersion. ImmunityBio ranks 334 out of 507 within the biotechnology sector.

## The Week Ahead

The US macro calendar is heavier next week. NFIB small business optimism lands on 8 September, with a prior reading of 99.8. On 10 September, final demand PPI, initial jobless claims, existing home sales and wholesale sales are all due, with PPI expected to accelerate. No company-specific earnings or events are scheduled within the week, but hotter inflation prints could shift risk appetite for biotech names and feed into volatility.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md)

## Related News & Research

- [ImmunityBio partners with Accord Healthcare, Uniphar to expand ANKTIVA access in Europe](https://longbridge.com/en/news/304281581.md)
- [Biotech Stocks Facing FDA Decision In November 2026](https://longbridge.com/en/news/303519995.md)
- [ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment](https://longbridge.com/en/news/302309717.md)
- [Qualcomm Could Swing $14.4 Billion In Value After Earnings](https://longbridge.com/en/news/304162725.md)
- [Marvell Technology, Inc. $MRVL Shares Newly Bought by Integrity Alliance LLC.](https://longbridge.com/en/news/304246972.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**